{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:31:07Z","timestamp":1771306267953,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"am","delay-in-days":313,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejca.2023.113289","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T16:18:15Z","timestamp":1691770695000},"page":"113289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Hyperprogression in advanced melanoma is not restricted to immunotherapy"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4354-0778","authenticated-orcid":false,"given":"Marie","family":"Fournier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Dereure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Dalac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastien","family":"Oriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9leste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejca.2023.113289_bib1","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113289_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.678409","article-title":"Hyperprogressive disease in cancers treated with immune checkpoint inhibitors","volume":"12","author":"Shen","year":"2021","journal-title":"Front Pharmacol"},{"issue":"Suppl.3","key":"10.1016\/j.ejca.2023.113289_bib3","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.21037\/jtd.2019.01.97","article-title":"Hyperprogressive disease: a distinct effect of immunotherapy?","volume":"11","author":"Popat","year":"2019","journal-title":"J Thorac Dis"},{"issue":"11","key":"10.1016\/j.ejca.2023.113289_bib4","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive disease in patients with advanced non\u2013small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy","volume":"4","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.113289_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3389\/fimmu.2020.00492","article-title":"How can immune checkpoint inhibitors cause hyperprogression in solid tumors?","volume":"11","author":"Denis","year":"2020","journal-title":"Front Immunol"},{"issue":"15","key":"10.1016\/j.ejca.2023.113289_bib6","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2023.113289_bib7","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2023.113289_bib8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/cncr.31999","article-title":"Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities","volume":"125","author":"Kanjanapan","year":"2019","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2023.113289_bib9","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3390\/cancers11111699","article-title":"Hyperprogressive disease during anti-PD-1 (PDCD1) \/ PD-L1 (CD274) therapy: a systematic review and meta-analysis","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ejca.2023.113289_bib10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1634\/theoncologist.2019-0636","article-title":"Hyperprogression and immune checkpoint inhibitors: hype or progress?","volume":"25","author":"Adashek","year":"2020","journal-title":"The Oncologist"},{"issue":"3","key":"10.1016\/j.ejca.2023.113289_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.1839","article-title":"Hyperprogression in patients with cancer receiving immune checkpoint inhibitors","volume":"4","author":"Sehgal","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"Suppl.15","key":"10.1016\/j.ejca.2023.113289_bib12","article-title":"Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials","volume":"36","author":"Matos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113289_bib13","article-title":"Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: aA systematic review and meta-analysis","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113289_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11307-020-01526-4","article-title":"Imaging characteristics and diagnostic performance of 2-deoxy-2-[18F]fluoro-D-Glucose PET\/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy","volume":"23","author":"Nakamoto","year":"2021","journal-title":"Mol Imaging Biol"},{"issue":"11","key":"10.1016\/j.ejca.2023.113289_bib15","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.3390\/ijms20112674","article-title":"Hyperprogression under immunotherapy","volume":"20","author":"Frelaut","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ejca.2023.113289_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/RLU.0000000000002849","article-title":"FDG PET findings of hyperprogression during immunotherapy in a patient with hepatocellular carcinoma","volume":"45","author":"Wang","year":"2020","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1016\/j.ejca.2023.113289_bib17","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00262-020-02716-3","article-title":"Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma","volume":"70","author":"Schuiveling","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.ejca.2023.113289_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.1136","article-title":"Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Park","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2023.113289_bib19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3389\/fimmu.2018.00797","article-title":"Hyperprogressive disease in anorectal melanoma treated by PD-1 inhibitors","volume":"9","author":"Faure","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ejca.2023.113289_bib20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3390\/cancers12030540","article-title":"MDM2, MDM4 and EGFR amplifications and hyperprogression in metastatic acral and mucosal melanoma","volume":"12","author":"Forschner","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejca.2023.113289_bib21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1078155219845436","article-title":"Hyperprogression after nivolumab for melanoma: a case report","volume":"26","author":"Yilmaz","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"10.1016\/j.ejca.2023.113289_bib22","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/1078155220949642","article-title":"Atypical response patterns in metastatic melanoma and renal cell carcinoma patients treated with nivolumab: a single center experience","volume":"27","author":"Yilmaz","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.ejca.2023.113289_bib23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1159\/000503095","article-title":"Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals","volume":"12","author":"Azam","year":"2019","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.ejca.2023.113289_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ctrv.2018.07.006","article-title":"Hyperprogression as a distinct outcome after immunotherapy","volume":"70","author":"Fuentes-Antr\u00e1s","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2023.113289_bib25","doi-asserted-by":"crossref","first-page":"x39","DOI":"10.1093\/annonc\/mdy511","article-title":"Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC","volume":"29","author":"Gandara","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.113289_bib26","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.3390\/ijms22073736","article-title":"Hyperprogressive disease: main features and key controversies","volume":"22","author":"Arasanz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2023.113289_bib27","doi-asserted-by":"crossref","first-page":"v405","DOI":"10.1093\/annonc\/mdx376.006","article-title":"Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) \u2013 analysis of somatic alterations (SAs)","volume":"28","author":"Singavi","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113289_bib28","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13046-020-01721-9","article-title":"Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don\u2019t) know","volume":"39","author":"Camelliti","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2023.113289_bib29","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","article-title":"Antibody-Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade","volume":"25","author":"Lo Russo","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2023.113289_bib30","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300391X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300391X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:06Z","timestamp":1760733666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492300391X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":30,"alternative-id":["S095980492300391X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113289","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperprogression in advanced melanoma is not restricted to immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113562","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113507","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113289"}}